ArticleHealth science reports2025
Burden of Osteoarthritis in Iran: A National and Subnational Perspective, 1990-2019 Global Burden of Disease Study.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- COLGALT2 Polymorphisms are Associated with Osteoarthritis Risk and Clinical Severity in a Chinese Population.International journal of general medicine · 2026Article
- Topical Effects of Tarragon Oil Extract on Pain Intensity, Stiffness, and Physical Function of the Knee Joint in Patients with Osteoarthritis: A Randomized Controlled Clinical Trial.Iranian journal of nursing and midwifery researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Osteoarthritis (OA) is a chronic degenerative joint disease caused by pro-inflammatory factors and protease activity, leading to progressive joint destruction. The data on a global scale indicate a substantial rise in OA. This study evaluates the burden of OA in Iran, given its high impact and the limited number of epidemiological studies on the condition. Methods: The data pertaining to the prevalence, years lived with disability (YLD), and incidence and age-standardized rates of OA in Iran and its subnational regions were retrieved using the Global Burden of Disease Study (GBD) Results Tool. Results: Age-standardized prevalence rate (ASPR) of OA in Iran was 5224.14 (4699.54-5821.43) and 5588.22 (5041.17-6228.61) in 1990 and 2019, which was lower than the global level. The knee was the most prevalent OA in both 1990 and 2019 in Iran, 3326.63 (2862.19-3841.62) and 3660.61 (3151.81-4228.27) respectively, followed by hand OA (1432.43 (1078.03-1922.21) in 1990 and 1476.24 (1107.91-1979.80) in 2019) and hip OA (239.08 (184.05-300.68) in 1990 and 277.65 (213.24-351.43) in 2019). The age-standardized YLD rate of OA in Iran was 180.96 (91.76-355.00) in 1990 and 195.27 (98.67-381.01) in 2019. The age-standardized YLD rate of site-specific OA followed the same trend as ASPR. Tehran province, followed by Alborz and Yazd provinces, had the highest ASPR of OA in 1990. In 2019, Tehran province (6144.94 (5526.53-6862.14)) remained at the first rank, followed by Mazandaran (5536.591 (4974.13-6165.62)) and Alborz (5512.88 (4946.79-6138.54)) provinces. Our findings show that the OA incidence rate peaked in the 55-59 age group in both males and females in 1990 and 2019. Conclusion: Despite being lower than global averages, the prevalence, incidence, and YLD due to OA in Iran have significantly increased over the past three decades. This highlights the need for healthcare policymakers to implement comprehensive strategies to manage OA burden and costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.